GSK, Pfizer to merge consumer health businesses
GlaxoSmithKline will have a controlling 68% equity interest and Pfizer will have a 32% equity interest in the joint venture, which would have a global OTC market share of 7.3%, leading the market in most key geographical areas, including the United States and China.